CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Biologics to Roll Out ‘Mission 10 cents’ in Philippines; Signs MoU with 2 Municipal Governments & reach52 to enable Affordable Access to Quality Insulins
  • Wed, 30-Sep-2020
  • Posted by: BIOCON
No Comments

Biocon appoints Anupam Jindal as its Chief Financial Officer
  • Tue, 22-Sep-2020
  • Posted by: BIOCON
No Comments

Biocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
  • Mon, 31-Aug-2020
  • Posted by: BIOCON
No Comments

Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion.
  • Fri, 31-Jul-2020
  • Posted by: BIOCON
No Comments

Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr
  • Thu, 23-Jul-2020
  • Posted by: BIOCON
No Comments

Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
  • Tue, 21-Jul-2020
  • Posted by: BIOCON
No Comments

Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab for COVID-19
  • Mon, 13-Jul-2020
  • Posted by: BIOCON
No Comments

Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients
  • Sat, 11-Jul-2020
  • Posted by: BIOCON
No Comments

Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
  • Mon, 22-Jun-2020
  • Posted by: BIOCON
No Comments

Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
  • Fri, 12-Jun-2020
  • Posted by: BIOCON
No Comments

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2024, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>